Exec-Edge – Page 6 – ExecEdge

Ashvattha Therapeutics Appoints Robert J. Dempsey as Interim CEO

Ashvattha Therapeutics Appoints Robert J. Dempsey as Interim CEO

By Daniella Parra Ashvattha Therapeutics has appointed Robert J. Dempsey as Interim CEO, tapping an ophthalmology veteran with a track record of transformative deals and launches, they said. Recently, Ashvattha announced positive Phase 2 results for migaldendranib, a novel subcutaneous nanomedicine showing...

IP & Tech Partner Tigist Kassahun Joins Vinson & Elkins

IP & Tech Partner Tigist Kassahun Joins Vinson & Elkins

By Karen Roman Vinson & Elkins said Tigist Kassahun joined the firm as partner and will start working in Washington, D.C. before transitioning to New York. Ms. Kassahun previously served at Debevoise & Plimpton and her experience focuses on the...

Lisata Therapeutics Partners with Catalent on ADC Technology

Lisata Therapeutics Partners with Catalent on ADC Technology

By Karen Roman Lisata Therapeutics, Inc. (Nasdaq: LSTA) said it started a global product license agreement with Catalent, Inc., enabling the latter to include Lisata’s certepetide into antibody-drug conjugates (ADCs) developed using Catalent’s SMARTag technology platform. The partnership is a...

Input your search keywords and press Enter.